Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

Mechanistic basis of G595R-mediated resistance to entrectinib in TRK kinase: a structural-energetic perspective

Min-Yu Li Xu Jiang Tingting Du Shenqian Xu Wuxia Liu Xiaoou Qiu Wenqi Liang Guodong Zheng Jingfeng Zhang Wei Wang
Aug 2026 · Journal of Molecular Modeling · Vol 32 · 0 citations · 42 references
Medicine

TL;DR

These findings provide a mechanistic explanation for entrectinib resistance at atomic resolution and illustrate how a single-point mutation can trigger long-range perturbations in protein dynamics and interdomain communication.

DOI PubMed Semantic Scholar
View source

Similar papers

Sep 2026

Therapeutic targeting of cancer-associated PKM2 mutants by shikonin via mutation-induced pocket recognition.

This study demonstrates that PKM2 mutations dynamically remodel the binding pocket and allosteric communication to facilitate shikonin recognition, highlighting the newly identified pocket as a promising therapeutic site for future PKM2 targeted drug design.

Anandita Mitra, Sandip Paul · 0 citations
Aug 2026

In Silico Exploration of Novel EGFR T790M and C797S Resistance with Mutant-Selective Allosteric Inhibitors Using a Hybrid Computational Approach

A number of lead candidates with strong EGFR inhibitory potential, promising pharmacokinetic profiles, and mutant selectivity were successfully identified by the integrated computational approach.

M. Kendre, S. S. Bhusari, Pravin S. Wakte · 0 citations
Open access Sep 2026

Drugging the “undruggable” p53: a structure-guided strategy against the Y220C mutation

Complementary strategies, including covalent stabilization and targeted degradation, further extend this framework, establishing mutation-encoded structural vulnerabilities as actionable therapeutic opportunities, in which oncogenic missense mutations can generate druggable neo-pockets.

Lin-Wan Song, Hua Wang · 0 citations
Review Open access Sep 2026

Molecular landscape of KRAS G12C inhibitor resistance and rational combination strategies in cancer therapy

Background: Oncogenic alterations in KRAS are among the most frequent driver mutations in human cancers, particularly lung, colorectal, and pancreatic cancers. Mutant KRAS was historically considered an “undruggable” target because of its high affinity for guanosine triphosphate and guanosine diphosphate (GDP) and the...

V. Adhao, Sakshi N. Patil · 0 citations
Sep 2026

Computational Elucidation of Potent Ligands Targeting Recalcitrant ALK G1202R‐Associated Double Mutations Underlying Lorlatinib Resistance

Targeting ALK has become a viable therapeutic strategy in non‐small cell lung cancer (NSCLC) following the discovery of the EML4‐ALK fusion. Several inhibitors were developed which improved the patient's outcomes; however, the emergence of drug resistance limits the treatment and poses significant challenges. The s...

P. Bharath, Mohanraj Gopikrishnan, Magesh Ramasamy et al. · 0 citations
Open access Aug 2026

Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Current tyrosine kinase inhibitors (TKIs) targeting oncogenic KIT and PDGFRA have improved patient outcomes, yet off-target toxicities and drug resistance mutations remain major clinical challenges. Many approve...

T. Schulz, M. Beerbaum, A. Scrima et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.